Multisystem Inflammatory Syndrome in Children With COVID-19 in Mumbai, India.
Multisystem Inflammatory Syndrome in Children With COVID-19 in Mumbai, India.
复制标题
DOI：
10.1007/s13312-020-2026-0
复制
发表时间：
2020-11-15
影响因子：
2.3
通讯作者：
Kulkarni S
中科院分区：
文献类型：
--
作者：
Jain S;Sen S;Lakshmivenkateshiah S;Bobhate P;Venkatesh S;Udani S;Shobhavat L;Andankar P;Karande T;Kulkarni S
我们描述了印度孟买大都市区COVID-19（MIS-C）多系统炎症综合征儿童的表现、治疗和结局。这是一项在孟买的四家三级医院进行的观察性研究。从2020年5月1日至2020年7月15日期间接受MIS-C（根据WHO标准）治疗的患者的患者住院记录中获得参数，包括人口统计学、血液学、实验室标志物、药物和结局。纳入了23例患者（11例男性），中位（范围）年龄为7.2（0.8-14）岁。COVID-19 RT-PCR或抗体阳性率分别为39.1%和30.4%; 34.8%有阳性接触者。65%的患者出现休克;与未发生休克的儿童相比，这些儿童的年龄较高（P=0.05），心肌炎伴肌钙蛋白、NT pro BNP升高和左心室功能不全的发生率显著较高，沿着明显的嗜中性粒细胞增多和淋巴细胞减少。26%的患者出现冠状动脉扩张。类固醇最常用于治疗（96%），通常沿着静脉注射免疫球蛋白（IVIg）（65%）。结局良好，仅1例死亡。介绍了印度MIS-C的初步数据。需要对MIS-C患者进行进一步的研究和更长时间的监测，以改善我们的诊断，治疗和监测标准。
We describe the presentation, treatment and outcome of children with multisystem inflammatory syndrome with COVID-19 (MIS-C) in Mumbai metropolitan area in India. This is an observational study conducted at four tertiary hospitals in Mumbai. Parameters including demographics, symptomatology, laboratory markers, medications and outcome were obtained from patient hospital records and analyzed in patients treated for MIS-C (as per WHO criteria) from 1 May, 2020 to 15 July, 2020. 23 patients (11 males) with median (range) age of 7.2 (0.8–14) years were included. COVID-19 RT-PCR or antibody was positive in 39.1% and 30.4%, respectively; 34.8% had a positive contact. 65% patients presented in shock; these children had a higher age (P=0.05), and significantly higher incidence of myocarditis with elevated troponin, NT pro BNP and left ventricular dysfunction, along with significant neutrophilia and lymphopenia, as compared to those without shock. Coronary artery dilation was seen in 26% patients overall. Steroids were used most commonly for treatment (96%), usually along with intravenous immunoglobulin (IVIg) (65%). Outcome was good with only one death. Initial data on MIS-C from India is presented. Further studies and longer surveillance of patients with MIS-C are required to improve our diagnostic, treatment and surveillance criteria.
登录
查看更多内容
影响因子：
37.8
作者：
McCrindle, Brian W.;Rowley, Anne H.;Pahl, Elfriede
通讯作者：
Pahl, Elfriede
影响因子：
37.8
作者：
McCrindle, Brian W.;Li, Jennifer S.;Newburger, Jane W.
通讯作者：
Newburger, Jane W.
影响因子：
158.5
作者：
Dufort, Elizabeth M.;Koumans, Emilia H.;Zucker, Howard
通讯作者：
Zucker, Howard
影响因子：
158.5
作者：
Feldstein, Leora R.;Rose, Erica B.;Randolph, Adrienne G.
通讯作者：
Randolph, Adrienne G.
影响因子：
120.7
作者：
Whittaker, Elizabeth;Bamford, Alasdair;Levin, Michael
通讯作者：
Levin, Michael